Reduced responsiveness to epoetin at re-exposure after prolonged epoetin-free period in anemic hemodialysis patients with end-stage renal disease

Croatian Medical Journal

Volumn 47, Issue 3, 2006, Pages 424-432

  Milutinović, Slobodan ^a   Trkulja, Vladimir ^b  

^a Holy Ghost General Hospital   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCITRIOL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPOMAX; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON SACCHARATE; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33745196027     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Eknoyan G. The importance of early treatment of the anemia of chronic kidney disease. Nephrol Dial Transplant. 2001;16 Suppl 5:45-9.
2. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant. 2002;17 Suppl 1:53-9.
3. Ifudu O. Patient characteristics determining rHuEPO dose requirements. Nephrol Dial Transplant. 2002;17 Suppl 5:38-41.
4. Sunder-Plassmann G, Hörl WH. Novel aspects of erythropoietin response in renal failure patients. Nephrol Dial Transplant. 2001;16 Suppl 5:40-4.
5. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:439-46.
6. Levin A. Preaching and practice: evidence-based medicine and the accountability of nephrologists within the health care system. The implications of the findings of the costsaving potential of subcutaneous versus intravenous epoetin therapy. Am J Kindey Dis. 2002;40:662-3.
7. Hynes DM, Stroupe KT, Greer JW, Reda DJ, Frankenfield DL, Kaufman JS, et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med. 2002;112:169-75.
8. Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin Dial. 2006;19:146-51.
9. Horl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, et al. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. Nephrol Dial Transplant. 2005;20 Suppl 3:iii25-32.
10. Kokot F, Wiecek A. Evidence that the anemia of renal failure participates in overall uremic toxicity. Kindey Int Suppl. 1997;62:S83-6.
11. Milutinović S, Plavljanić Crossed D sign, Trkulja V. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. Fundam Clin Pharmacol. In press 2006.
12. Association for the Advancement of Medical Instrumentation. American national standards for hemodialysis systems. In: AAMI standards and recommended practices (vol 3). Arlington (VA): AAMI; 1990. p. 35-54.
13. Water for diluting concentrated hemodialysis solutions. In: Schnadelbach D, editor. European pharmacopoeia. 3rd ed. Strasbourg: The European Department for the Quality of Medicines, Council of Europe; 1997. p. 923-5.
14. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL. Once-weekly compared with three- three-times-weekly subcutaneous epoetin beta: results form a randomized, multicenter therapeutic-equivalence study. Am J Kindey Dis. 2002;40:119-25.
15. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1 - correlation within subjects. BMJ. 1995;310:446.
16. Schultz CJ, Neil HA, Dalton RN, Konopelska Bahu T, Dunger DB; Oxford Regional Prospective Study Group. Blood pressure does not rise before the onset of microalbuminuria in children followed from diagnosis of type 1 diabetes. Oxford Regional Prospective Study Group. Diabetes Care. 2001;24:555-60.
17. Kletzmayr J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Horl WH, et al. Anemia and carnitine supplementation in hemodialyzed patients. Kindey Int Suppl. 1999;69:S93-106.
18. European Medicines Agency; Committee for Medicinal Products for Human Use. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on biosimilar medicinal products containing recombinant erythropoietins. Available at: http://www.emea.eu.int/pdfs/human/biosimilar/ 9452605en.pdf. Accessed: April 5, 2006.
19. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol. 2002;13:1288-95.
20. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kindey Dis. 1999;33:63-72.
21. Drueke TB, Eckardt KU. Role of secondary hyperparathyoridism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant. 2002;17 Suppl 5:28-31.
22. Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-Garcia R, Valderrabano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron. 1998;78:23-7.